toosendanin has been researched along with Bone Cancer in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beutler, JA; Goetz, M; Goncharova, EI; Hao, X; Henrich, CJ; Huang, S; Jia, L; Kambala, A; Khanna, C; LeBlanc, A; Long, SA; Ren, L; Wilson, J; Yang, X | 1 |
| Cai, Z; Hua, Y; Li, J; Lin, B; Wang, G; Wang, H; Wang, Z; Xu, J; Yin, F; Zhang, T; Zuo, D | 1 |
2 other study(ies) available for toosendanin and Bone Cancer
| Article | Year |
|---|---|
Identification of potential modulators of osteosarcoma metastasis by high-throughput cellular screening of natural products.
Topics: Biological Products; Bone Neoplasms; Cell Line; Cell Movement; Cell Proliferation; Cell Survival; Drugs, Chinese Herbal; High-Throughput Screening Assays; Humans; Lovastatin; Melia; Monascus; Osteosarcoma; Plant Extracts; Pyridines; Seeds | 2021 |
Toosendanin demonstrates promising antitumor efficacy in osteosarcoma by targeting STAT3.
Topics: Animals; Bone Neoplasms; Carcinogenesis; Cell Line, Tumor; Drugs, Chinese Herbal; ErbB Receptors; Humans; Male; Meliaceae; Mice; Mice, Inbred BALB C; Mice, Nude; Osteosarcoma; Phosphorylation; Plant Bark; Protein Multimerization; src Homology Domains; STAT3 Transcription Factor; Surface Plasmon Resonance; Xenograft Model Antitumor Assays | 2017 |